BioSpace News Archive

Verona Pharma plc announced the closing of its upsized public offering of 14,260,000 American Depositary Shares, each representing eight ordinary shares of Verona Pharma, nominal value £0.05 per share, at a price to the public of $10.50 per ADS, which includes the exercise in full by the underwriters of their option to purchase an additional 1,860,000 ADSs.

Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today provided a corporate update and reported financial results for the second quarter ended June 30, 2022.

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced second quarter 2022 results and provided a corporate update.

T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced financial results for the second quarter ended June 30, 2022.

Lucira Health, Inc., a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, reported financial results for the second quarter ended June 30, 2022 and provided business updates.

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease, today reported financial results for the quarter ended June 30, 2022 and provided a business update.

TELA Bio, Inc. announced that it has commenced an underwritten public offering of shares of its common stock.

NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells for liquid and solid malignancies, today reported financial results for the second quarter of 2022.

Calithera Biosciences, Inc., a clinical-stage, precision-oncology biopharmaceutical company, announced its financial results for the second quarter ended June 30, 2022.

IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), today reported financial results as of and for the six months June 30, 2022 and operational and commercial highlights for the second quarter.